New Research Highlight from EU-METAHEART consortium “Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage” by Panagiota-Efstathia Nicolau, Ioanna Andreadou and collaborators. The study explores the cardioprotective effects of empagliflozin in acute myocardial infarction.
The translational study reveals that empagliflozin can reverse endothelial transcriptome deregulation following reperfusion, reduce infarct size, and mitigate the no-reflow phenomenon, effectively preserving myocardial function. Furthermore, it highlights how empagliflozin decreases inflammation and prevents endothelial injury, improving cardiovascular health in diabetic patients, even during long-term follow-up.
This important contribution supports EU-METAHEART’s goal of integrating molecular research and clinical application to improve cardiovascular outcomes in metabolic diseases.
Access the full publication here.
